Gosset Ownership
Public
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Comera Life Sciences General Information
Comera is developing subcutaneous (SQ) formulations of intravenous (IV) biologics. Their lead candidate CLS-001 is a SQ formulation of vedolizumab for IBD. They have validated their caffeine-based excipient formulation in four preclinical studies without evidence of local or systemic toxicity.
Contact Information
Primary Industry
Biotech
Corporate Office
Woburn, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Regeneron
Comera Life Sciences Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Jan 4, 2024 | $1.5M | Completed | Preclinical |
To view Comera Life Sciences's complete valuation and funding history, request access »
Comera Life Sciences Financial Metrics
Market Cap
$3.1K
Total Revenue
$136.3K
Enterprise Value
$-1593200